Danaher (DHR) Is A Key Supplier In Fast Growing Bioprocessing Markets
A Memo To Danaher's Biotechnology Team About Turning Orders Into Sales
Danaher’s Cepheid business to lay off 67 people in California
Insider Move: Matthew McGrew Exercises Options, Realizing $2.56M At Danaher
VTRS or DHR: Which Is the Better Value Stock Right Now?
Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus
Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript
Danaher (DHR) Stock Fair Value Rises After Higher Analyst Targets And Q3 Commentary
Danaher (DHR) Wins FDA Clearance For Hemorrhagic Fever Test With Four Virus Detection
Danaher (DHR) Stock Looks Fully Priced Despite Its 18% Three Year Gain
Learn Why The Bull Case For Danaher (DHR) Could Change Following FDA Test Clearance
Danaher (DHR), Why Is It Drawing Fresh Attention Today?
Danaher (NYSE:DHR) Sets Up for Breakout With Strong Technical Ratings
Danaher Companies Integrated DNA Technologies And Aldevron Jointly Launch New Research-Grade mRNA Solutions Designed For Base And Prime Editing Workflows
Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences
Matthew McGrew At Danaher Capitalizes: Options Exercised, Resulting In $2.45M
At Danaher, Christopher Bouda Chooses To Exercise Options, Resulting In $1.23M
Danaher (DHR) Upgraded to Buy: Here's Why
Billionaire Investor Adds to Danaher Stake After Cutting It Earlier This Year
What Does Danaher (DHR) FDA Clearance For AI AFib Detection Mean Now?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.